Targeted Cancer Therapies
M-Cdk Drives Transition Into Mitosis
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Dec 26, 2025

Detection of Rare Mutations in CtDNA Using Next Generation Sequencing
Published on: August 24, 2017
In the plasmaMATCH trial, patients with advanced breast cancer received targeted therapies based on circulating tumor DNA testing. HER2 and AKT1 mutations showed promising response rates over 22% with lasting benefits.
Area of Science:
Background: